文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

革兰阴性菌医院获得性肺炎和呼吸机相关性肺炎危重患者单药与联合抗菌治疗:多中心回顾性队列研究

Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study.
PubMed 文献 · Crit Care · 2024-01-03
一句话结论革兰阴性菌所致HAP/vHAP/VAP危重患者中,初始联合抗菌治疗与单药治疗相比,28天死亡、14天临床治愈及7天死亡或AKI风险均无独立差异。

本研究基于前瞻性多中心OutcomeRea数据库,纳入391例由单一革兰阴性菌所致首次HAP、vHAP或VAP并接受初始恰当单药或联合治疗的危重患者,其中单药治疗151例(38.6%)、联合治疗240例(61.4%)。主要终点28天全因死亡率为31.2%,14天临床治愈率为43.7%,7天死亡或治疗所致急性肾损伤(AKI)复合终点率为41.2%,两组间均无显著差异。经逆概率治疗加权回归分析,联合治疗与28天全因死亡(aOR 1.14;95%CI 0.73-1.77;P=0.56)、14天临床治愈(aOR 0.79;95%CI 0.53-1.20;P=0.27)及7天死亡或AKI(aOR 1.07;95%CI 0.71-1.63;P=0.73)均无独立关联。多变量回归模型和亚组分析结果相似。结论提示初始联合治疗对上述结局无独立影响。

要点

  • 在391例革兰阴性菌所致HAP/vHAP/VAP危重患者中,联合治疗与单药治疗的28天全因死亡率无显著差异(总体31.2%)。
  • 逆概率治疗加权分析显示,联合治疗与28天全因死亡无独立关联(aOR 1.14;95%CI 0.73-1.77;P=0.56)。
  • 联合治疗与14天临床治愈无独立关联(aOR 0.79;95%CI 0.53-1.20;P=0.27)。
  • 联合治疗与7天死亡或治疗所致AKI复合终点无独立关联(aOR 1.07;95%CI 0.71-1.63;P=0.73),且未观察到AKI风险增加。
  • 多变量回归模型和亚组分析(按耐药表型、药物类别、联合疗程、SOFA评分等划分)结果与主要分析相似。

适用人群与场景

  • 纳入标准:来自前瞻性多中心OutcomeRea数据库、首次发生HAP、vHAP或VAP且由单一革兰阴性菌所致、并接受初始恰当单药或联合治疗的危重患者。
  • 疾病类型分布:VAP占67.3%,vHAP占16.4%,HAP占16.4%。

研究设计与关键结果

  • 研究类型:多中心回顾性队列研究,基于前瞻性多中心OutcomeRea数据库,纳入391例危重患者。
  • 分组:单药治疗组151例(38.6%),联合治疗组240例(61.4%)。
  • 主要终点:28天全因死亡率总体31.2%,两组间无显著差异;逆概率治疗加权分析显示联合治疗与28天全因死亡无独立关联(aOR 1.14;95%CI 0.73-1.77;P=0.56)。
  • 次要终点:14天临床治愈率总体43.7%,两组间无显著差异;联合治疗与14天临床治愈无独立关联(aOR 0.79;95%CI 0.53-1.20;P=0.27)。
  • 次要终点:7天死亡或治疗所致AKI复合终点率总体41.2%,两组间无显著差异;联合治疗与7天死亡或AKI无独立关联(aOR 1.07;95%CI 0.71-1.63;P=0.73)。
  • 亚组分析:根据致病菌耐药表型(多重耐药或非多重耐药)、关键药物类别(碳青霉烯类或其他)和辅助药物类别(氨基糖苷类/多粘菌素类或其他)、联合治疗持续时间(<3天或≥3天)、肺炎发生时SOFA评分(<7分或≥7分),以及非发酵革兰阴性菌肺炎、肺炎相关血流感染或感染性休克患者进行的亚组分析结果相似;多变量回归模型结果也相似。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在革兰阴性菌所致HAP、vHAP或VAP的危重患者中,初始联合抗菌治疗对28天死亡率、14天临床治愈率及7天死亡或AKI风险无独立影响,未观察到AKI风险增加。
  • 亚组分析(包括多重耐药菌、碳青霉烯类联合氨基糖苷类/多粘菌素类、联合疗程≥3天、SOFA评分≥7分、非发酵菌、肺炎相关血流感染、感染性休克)结果与主要分析相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

KEY MESSAGES: In this study including 391 critically ill patients with nosocomial pneumonia due to Gram-negative pathogens, combination therapy was not associated with a reduced hazard of death at Day 28 or a greater likelihood of clinical cure at Day 14. No over-risk of AKI was observed in patients receiving combination therapy.

BACKGROUND: The benefits and harms of combination antimicrobial therapy remain controversial in critically ill patients with hospital-acquired pneumonia (HAP), ventilated HAP (vHAP) or ventilator-associated pneumonia (VAP) involving Gram-negative bacteria.

METHODS: We included all patients in the prospective multicenter OutcomeRea database with a first HAP, vHAP or VAP due to a single Gram-negative bacterium and treated with initial adequate single-drug or combination therapy. The primary endpoint was Day-28 all-cause mortality. Secondary endpoints were clinical cure rate at Day 14 and a composite outcome of death or treatment-emergent acute kidney injury (AKI) at Day 7. The average effects of combination therapy on the study endpoints were investigated through inverse probability of treatment-weighted regression and multivariable regression models. Subgroups analyses were performed according to the resistance phenotype of the causative pathogens (multidrug-resistant or not), the pivotal (carbapenems or others) and companion (aminoglycosides/polymyxins or others) drug classes, the duration of combination therapy (< 3 or ≥ 3 days), the SOFA score value at pneumonia onset (< 7 or ≥ 7 points), and in patients with pneumonia due to non-fermenting Gram-negative bacteria, pneumonia-related bloodstream infection, or septic shock.

RESULTS: Among the 391 included patients, 151 (38.6%) received single-drug therapy and 240 (61.4%) received combination therapy. VAP (overall, 67.3%), vHAP (16.4%) and HAP (16.4%) were equally distributed in the two groups. All-cause mortality rates at Day 28 (overall, 31.2%), clinical cure rate at Day 14 (43.7%) and the rate of death or AKI at Day 7 (41.2%) did not significantly differ between the groups. In inverse probability of treatment-weighted analyses, combination therapy was not independently associated with the likelihood of all-cause death at Day 28 (adjusted odd ratio [aOR], 1.14; 95% confidence interval [CI] 0.73-1.77; P = 0.56), clinical cure at Day 14 (aOR, 0.79; 95% CI 0.53-1.20; P = 0.27) or death or AKI at Day 7 (aOR, 1.07; 95% CI 0.71-1.63; P = 0.73). Multivariable regression models and subgroup analyses provided similar results.

CONCLUSIONS: Initial combination therapy exerts no independent impact on Day-28 mortality, clinical cure rate at Day 14, and the hazard of death or AKI at Day 7 in critically ill patients with mono-bacterial HAP, vHAP or VAP due to Gram-negative bacteria.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Barbier F, Dupuis C, Buetti N, et al. Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study. Crit Care. 2024. PMID: 38172969. doi:10.1186/s13054-023-04792-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。